Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.88 Average Price Target from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, thirteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $59.5625.

A number of analysts have commented on the stock. Barclays lowered their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Wall Street Zen lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a report on Thursday, March 12th. Finally, Truist Financial raised shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th.

Insider Activity

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. The trade was a 9.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Crombez sold 7,029 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares of the company’s stock, valued at $1,739,662.80. This represents a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 117,262 shares of company stock worth $2,687,403. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Amundi acquired a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at $318,000. EverSource Wealth Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,845 shares during the period. California State Teachers Retirement System grew its holdings in shares of Ultragenyx Pharmaceutical by 25.6% in the 1st quarter. California State Teachers Retirement System now owns 104,650 shares of the biopharmaceutical company’s stock valued at $2,192,000 after buying an additional 21,313 shares during the period. Eagle Health Investments LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at $18,522,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Ultragenyx Pharmaceutical by 36.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 451,119 shares of the biopharmaceutical company’s stock valued at $9,451,000 after buying an additional 119,950 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $23.94 on Friday. The company has a 50 day moving average price of $23.43 and a 200 day moving average price of $25.82. Ultragenyx Pharmaceutical has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The stock has a market capitalization of $2.36 billion, a PE ratio of -3.92 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the firm earned ($1.57) EPS. The business’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, equities analysts expect that Ultragenyx Pharmaceutical will post -4.62 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.